11 recruiting. 11 Phase 2, 8 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 11 |
| Phase 3 | 8 | Recruiting 8 |
| Phase 1 | 1 | Recruiting 1 |
Follow Haematological Malignancy: new trials by email Literature Review of Haematological Malignancy trials Research Report on Haematological Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial genotype-directed dosing with dosing software based on therapeutic drug monitoring - Fungal Infection, Haematological Malignancy | Phase 2 | Recruiting | The University of Queensland | 104 | 2025-04-14 | 2026-04-16 |
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Alectinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-12-18 | 2025-11-24 |
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins - Haematological Malignancy, Hypogammaglobulinemia | Phase 2 / Phase 3 | Recruiting | Monash University | 300 | 2022-11-30 | 2024-04-19 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2026-11-10 |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies CCS1477, Pomalidomide, Dexamethasone - Haematological Malignancy, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | CellCentric Ltd. | 250 | 2019-08-09 | 2026-06-24 |
Hematologic Neoplasms (11) · Neoplasms (9) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Glioma (4) · Lymphoproliferative Disorders (4) · Colorectal Neoplasms (3) · Multiple Myeloma (3) · Ovarian Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Erdheim-Chester Disease (2) · Infections (2) · Laryngeal Neoplasms (2) · Lymphoma (2) · Melanoma (2)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Neoplasms by Site (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Blood Protein Disorders (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Female Urogenital Diseases (4)
Vemurafenib (3) · alectinib (3) · cobimetinib (3) · dabrafenib (3) · entrectinib (3) · trametinib (3) · Trastuzumab (2) · atezolizumab (2) · capmatinib (2) · pertuzumab (2) · Amoxicillin (1) · Azacitidine (1) · Bortezomib (1) · CCS1477 (1) · Ciprofloxacin (1)
Cancer Research UK (7) · CellCentric Ltd. (1) · Helsinki University Central Hospital (1) · Monash University (1) · The University of Queensland (1)
United Kingdom (8) · Australia (2) · United States (2) · Finland (1) · France (1) · Spain (1) · Sweden (1)
Matthew Krebs, Dr (6) · Jason A Roberts, PhD (1) · Katriina Jalkanen, MD, PhD (1) · Matthew Krebs (1) · Prof Erica Wood (1) · Prof Zoe McQuilten (1) · Tim Somervaille (1)